{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:53:13Z","timestamp":1790855593450,"version":"4.1.0"},"reference-count":44,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T00:00:00Z","timestamp":1628294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["401821119\/GRK2504"],"award-info":[{"award-number":["401821119\/GRK2504"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Human cytomegalovirus (HCMV), by primary infection or reactivation, represents a great risk for immune-suppressed or compromised patients. In immunocompetent humans, the immune system suppresses the spread of HCMV during an infection, resulting in a mostly asymptomatic or mild course of the disease, whereas in immune suppressed patients, the compromised host immune response cannot control the viral infection. Multiple viral immunomodulatory mechanisms additionally contribute to immune evasion. Use of chimeric antigen receptors (CARs), a treatment strategy adapted from cancer immunotherapy, is investigated for possible application to combat HCMV and other infections in immunocompromised patients. The administration of CAR+ T-cells directed against HCMV antigens can bypass viral immune evasion and may complement existing treatment methods. This review gives a short overview of HCMV, the obstacles of current treatment options as well as a brief introduction to CARs and the current research situation on CAR+ T-cells against HCMV.<\/jats:p>","DOI":"10.3390\/v13081563","type":"journal-article","created":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T21:35:40Z","timestamp":1628458540000},"page":"1563","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["CARs\u2014A New Perspective to HCMV Treatment"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3722-779X","authenticated-orcid":false,"given":"Christopher","family":"Bednar","sequence":"first","affiliation":[{"name":"Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8873-3863","authenticated-orcid":false,"given":"Armin","family":"Ensser","sequence":"additional","affiliation":[{"name":"Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","article-title":"How we treat cytomegalovirus in hematopoietic cell transplant recipients","volume":"113","author":"Boeckh","year":"2009","journal-title":"Blood"},{"key":"ref_2","unstructured":"Robert Koch Institut (2021, June 30). Zytomegalievirus-Infektion: RKI Ratgeber. Available online: https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Merkblaetter\/Ratgeber_Zytomegalievirus.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1016\/j.transproceed.2018.02.091","article-title":"Resistant Cytomegalovirus Infection in Solid-organ Transplantation: Single-center Experience, Literature Review of Risk Factors, and Proposed Preventive Strategies","volume":"50","author":"Majeed","year":"2018","journal-title":"Transplant. Proc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2147\/IDR.S180908","article-title":"Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: An evidence-based review","volume":"12","author":"Helou","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1128\/CMR.00034-08","article-title":"Immunobiology of human cytomegalovirus: From bench to bedside","volume":"22","author":"Crough","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/cmi.2014.105","article-title":"Classical and non-classical MHC I molecule manipulation by human cytomegalovirus: So many targets\u2014but how many arrows in the quiver?","volume":"12","author":"Halenius","year":"2015","journal-title":"Cell. Mol. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00281-014-0448-2","article-title":"CMV-encoded Fc\u03b3 receptors: Modulators at the interface of innate and adaptive immunity","volume":"36","author":"Hoffmann","year":"2014","journal-title":"Semin. Immunopathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1126\/science.1352912","article-title":"Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones","volume":"257","author":"Riddell","year":"1992","journal-title":"Science"},{"key":"ref_9","first-page":"S78","article-title":"Selective reconstitution of CD8+ cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones","volume":"14","author":"Riddell","year":"1994","journal-title":"Bone Marrow Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/bloodadvances.2019000371","article-title":"\u201cMini\u201d bank of only 8 donors supplies CMV-directed T cells to diverse recipients","volume":"3","author":"Tzannou","year":"2019","journal-title":"Blood Adv."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"J. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V96.5.1999","article-title":"Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells","volume":"96","author":"Brocker","year":"2000","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1084\/jem.188.4.619","article-title":"Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes","volume":"188","author":"Krause","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.4049\/jimmunol.167.11.6123","article-title":"Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28\/CD3 zeta signaling receptor molecule","volume":"167","author":"Hombach","year":"2001","journal-title":"J. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"Hamieh","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","article-title":"Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor","volume":"32","author":"Kochenderfer","year":"2009","journal-title":"J. Immunother."},{"key":"ref_18","unstructured":"(2021, June 30). KYMRIAH (Tisagenlecleucel), Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/kymriah-tisagenlecleucel."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor\u2014Modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin\u2019s Lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-18-0426","article-title":"A Phase I\/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia","volume":"24","author":"Enblad","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: Chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s42003-020-1021-2","article-title":"convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting","volume":"3","author":"Landgraf","year":"2020","journal-title":"Commun. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrmicro2548","article-title":"Fusing structure and function: A structural view of the herpesvirus entry machinery","volume":"9","author":"Connolly","year":"2011","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Bootz, A., Karbach, A., Spindler, J., Kropff, B., Reuter, N., Sticht, H., Winkler, T.H., Britt, W.J., and Mach, M. (2017). Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006601"},{"key":"ref_27","unstructured":"Karbach, A. (2012). Protection from Cytomegalovirus Infection by Glycoprotein-specific Monoclonal Antibodies: Schutz vor Infektion mit dem Cytomegalievirus durch glykoproteinspezifische monoklonale Antik\u00f6rper. [Ph.D. Thesis, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg]."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1099\/0022-1317-78-8-1981","article-title":"The human cytomegalovirus glycoprotein B gene (ORF UL55) is expressed early in the infectious cycle","volume":"78","author":"Smuda","year":"1997","journal-title":"J. Gen. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev-virology-110615-042422","article-title":"Human Cytomegalovirus Latency: Approaching the Gordian Knot","volume":"3","author":"Goodrum","year":"2016","journal-title":"Annu. Rev. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1128\/JVI.02117-09","article-title":"T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor","volume":"84","author":"Full","year":"2010","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3389\/fmicb.2016.00844","article-title":"Cytomegalovirus-Infected Cells Resist T Cell Mediated Killing in an HLA-Recognition Independent Manner","volume":"7","author":"Proff","year":"2016","journal-title":"Front. Microbiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1099\/vir.0.82958-0","article-title":"Anti-IE1 CD4+ T-cell clones kill peptide-pulsed, but not human cytomegalovirus-infected, target cells","volume":"88","author":"Delmas","year":"2007","journal-title":"J. Gen. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.immuni.2016.01.010","article-title":"In Vivo Killing Capacity of Cytotoxic T Cells Is Limited and Involves Dynamic Interactions and T Cell Cooperativity","volume":"44","author":"Halle","year":"2016","journal-title":"Immunity"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/jvi.55.2.264-273.1985","article-title":"Interstitial murine cytomegalovirus pneumonia after irradiation: Characterization of cells that limit viral replication during established infection of the lungs","volume":"55","author":"Reddehase","year":"1985","journal-title":"J. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1128\/jvi.61.10.3102-3108.1987","article-title":"CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity","volume":"61","author":"Reddehase","year":"1987","journal-title":"J. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12967-018-1394-x","article-title":"Turning the tables on cytomegalovirus: Targeting viral Fc receptors by CARs containing mutated CH2-CH3 IgG spacer domains","volume":"16","author":"Proff","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/gt.2015.4","article-title":"Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model","volume":"22","author":"Walseng","year":"2015","journal-title":"Gene Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1089\/hum.2019.149","article-title":"Adult and Cord Blood-Derived High-Affinity gB-CAR-T Cells Effectively React Against Human Cytomegalovirus Infections","volume":"31","author":"Olbrich","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/infdis\/jiaa171","article-title":"Chimeric Antigen Receptors Targeting Human Cytomegalovirus","volume":"222","author":"Ali","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"9712","DOI":"10.1128\/JVI.00852-16","article-title":"Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy","volume":"90","author":"Liu","year":"2016","journal-title":"J. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.omto.2020.08.005","article-title":"CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease","volume":"18","author":"Slabik","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/gutjnl-2014-308316","article-title":"Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein","volume":"65","author":"Sautto","year":"2016","journal-title":"Gut"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.gastro.2007.11.002","article-title":"T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes","volume":"134","author":"Bohne","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2013.04.047","article-title":"T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice","volume":"145","author":"Krebs","year":"2013","journal-title":"Gastroenterology"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/8\/1563\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:42:06Z","timestamp":1760164926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/8\/1563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,7]]},"references-count":44,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["v13081563"],"URL":"https:\/\/doi.org\/10.3390\/v13081563","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,7]]}}}